Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

FDA

FDA

6 results

Filter Results By

Filter Applied. Clear All

Latest Posts

September 13, 2024 Fact Sheet: Are Pro-Life State Laws Preventing Pregnant Women from Receiving Emergency Care? Fact Sheet: Are Pro-Life State Laws Preventing Pregnant Women from Receiving Emergency Care? September 10, 2024 New Study Reveals Increasing Severity and Frequency of Emergency Department Visits Following Use of Abortion Drugs New Study Reveals Increasing Severity and Frequency of Emergency Department Visits Following Use of Abortion Drugs September 4, 2024 Anti-abortion laws not to blame for OB-GYN shortages: Study Anti-abortion laws not to blame for OB-GYN shortages: Study
Reset All Filters
6 results
FDA

Written Testimony of Dr. Ingrid Skop on Interstate Travel for Abortion

On June 12, CLI VP of Medical Affairs Dr. Ingrid Skop testified on the issue of interstate travel for abortion before the Subcommittee on Federal Courts, Oversight, Agency Action, and Federal Rights of the U.S. Senate Committee on the Judiciary. Dr. Skop responded to a number of misconceptions about the alleged need for women to travel out of state for abortion.

charlotte-lozier-institute Charlotte Lozier Institute
June 18, 2024
Please login to bookmarkClose
featured-image
FDA

United Kingdom Data Deficiencies Influencing U.S. FDA Decisions

CLI's VP of Medical Affairs Ingrid Skop, together with Calum Miller, MD, and Kevin Duffy, MPH, recently published an article in Issues in Law & Medicine arguing that decisions by the FDA to pull back regulations on the abortion drug mifepristone in part relied on "flawed studies with significantly undercounted complications" from the U.K.

featured-image
FDA

New Study Reveals FDA Relied on Cherrypicked Data to Approve Dangerous Mail-Order Abortion Drugs

A new peer-reviewed article highlights major flaws in the data used by the U.S. Food and Drug Administration (FDA) to remove medical safeguards and in-person administering of abortion drugs. These flaws illustrate the ongoing problem of lack of quality abortion reporting data in the U.S. as well as in the United Kingdom.

FDA

Fact Sheet: Three Problems with the FDA’s Abortion Drugs Complications Data

The FDA’s abortion drugs complications data is woefully incomplete. From 2020-2022, the six states that report complications by type of procedure reported 1,004 total complications from drug-induced abortions. Meanwhile, the FDA Adverse Event Reporting System data reflects just 17 unduplicated abortion-related adverse events over this same period.

FDA

Filed: CLI Amicus Brief in SCOTUS Case FDA v. Alliance for Hippocratic Medicine

On March 26, SCOTUS will hear oral arguments in the case FDA v. Alliance for Hippocratic Medicine. In the case, AHM argues that the FDA's changes to regulations of the abortion drug mifepristone were "arbitrary and capricious." CLI filed a brief in support of AHM, arguing that abortion with mifepristone is not "safe," that the FDA's loosening of mifepristone regulations makes these safety concerns even worse, and that AHM et al. have standing, since they would suffer concrete injury under the current loosened mifepristone regulations, being at risk of finding themselves complicit in abortion procedures.

featured-image
FDA

Scientists to SCOTUS: FDA Harms Women & Doctors by Allowing Dangerous Mail-Order Abortion Drugs

As the nation’s leading pro-life scientific, statistical and research center, the Charlotte Lozier Institute has filed an amicus brief asking the Supreme Court to affirm the 5th U.S. Circuit Court of Appeals decision that found the FDA likely violated the law when it loosened safeguards on abortion drugs by allowing them to be sent by mail.

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image